Cargando...
Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance
Trastuzumab is an antibody-based therapy drug targeting HER2-overexpressing tumors. While it has been proven to be very successful initially, most patients eventually develop resistance to trastuzumab. The mechanism of drug resistance is not well understood. Identifying pathways that mediate trastuz...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5542228/ https://ncbi.nlm.nih.gov/pubmed/28507275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17415 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|